SCHEMBL4293503

SCHEMBL4293503

CCOC(=O)c1cn2c(n1)SC(c1ccccc1)C(c1ccc3c(c1)NC(=O)CO3)=C2

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 9/20 0.49
AR P10275 5/20 0.49
NR3C1 P04150 3/20 0.49
PGR P06401 3/20 0.49
KDM4E B2RXH2 4/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 4/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
CPT2 P23786 2/20 0.40
CPT1A P50416 2/20 0.40
CPT1B Q92523 2/20 0.40
PARP1 P09874 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289013 0.89 NR3C2 (0.54) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4296414 0.87 NR3C2 (0.53) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4290870 0.85 NR3C2 (0.56) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4295918 0.85 NR3C2 (0.51) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4295784 0.85 NR3C2 (0.54) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4286616 0.83 NR3C2 (0.54) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4295663 0.80 NR3C2 (0.56) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4286804 0.77 NR3C2 (0.69) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4297063 0.75 NR3C2 (0.54) NR3C2ARNR3C1PGRKDM4E
SCHEMBL4290789 0.73 NR3C2 (0.60) NR3C2ARNR3C1PGRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R NR3C2 1/4885AR 60/4885NR3C1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.